VJHemOnc Podcast Key HemOnc updates from ASCO 2025: myeloma, lymphoma, MPNs, & more!
Jun 30, 2025
Explore groundbreaking advancements in hematologic oncology from the recent ASCO annual meeting. Discover promising clinical trial results in multiple myeloma and myeloproliferative neoplasms, including significant findings on rusfertide and ematelstat. Learn about innovative strategies in non-Hodgkin lymphoma and CLL, with impressive survival rates for patients treated with zanabrutinib. Additionally, uncover exciting progress in BPDCN treatment, highlighting a remarkable 70% complete remission rate with a novel antibody drug conjugate. This is a treasure trove of cutting-edge medical insights.
AI Snips
Chapters
Transcript
Episode notes
MRD Negativity and New Myeloma Therapies
- MRD negativity is becoming a key frontline treatment endpoint for multiple myeloma.
- Subcutaneous isatuximab and novel cellular therapies show promise in improving patient outcomes and quality of life.
Rusfertide in Polycythemia Vera
- Rusfertide mimics hepcidin to restrict iron to the bone marrow, controlling red blood cell production in polycythemia vera.
- The phase 3 Verify trial shows it drastically reduces the need for phlebotomy and improves patient symptoms.
New Lymphoma and CLL Treatment Data
- Glofitimab combined with Gemox significantly improves PFS and overall survival in relapsed refractory DLBCL.
- Xanabrutinib delivers durable 5-year PFS and OS in CLL patients with deletion 17p, rivaling outcomes in non-deletion 17p cases.